• 1
    Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003;97:866873.
  • 2
    Veri A, D'Andrea MR, Bonginelli P, et al. Clinical usefulness of bisphosphonates in oncology: Treatment of bone metastases, antitumoral activity and effect on bone resorption markers. Int J Biol Markers 2007;22:2433.
  • 3
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:18091822.
  • 4
    Lipton A. Toward new horizons: The future of bisphosphonate therapy. Oncologist 2004;9 (Suppl 4):3847.
  • 5
    Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther 2005;5:817832.
  • 6
    Caraglia M, Santini D, Marra M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006;13:726.
  • 7
    Ashton JA, Farese JP, Milner RJ, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 2005;66:885891.
  • 8
    Farese JP, Ashton J, Milner R, et al. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro. In Vitro Cell Dev Biol Anim 2004;40:113117.
  • 9
    Poirier VJ, Huelsmeyer MK, Kurzman ID, et al. The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro. Vet Comp Oncology 2003;1:207215.
  • 10
    Clamp A, Danson S, Nguyen H, et al. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004;5:607616.
  • 11
    Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:5969.
  • 12
    Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:49254935.
  • 13
    Pectasides D, Nikolaou M, Farmakis D, et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 2005;25:14571463.
  • 14
    Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005;31 (Suppl 3):18.
  • 15
    Fan TM, De Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:7480.
  • 16
    Fan TM, De Lorimier LP, O'Dell-Anderson K, et al. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med 2007;21:431439.
  • 17
    Lacoste H, Fan TM, De Lorimier LP, et al. Urine N-telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med 2006;20:335341.
  • 18
    De Lorimier LP, Fan TM. Bone metabolic effects of single-dose zoledronate in healthy dogs. J Vet Intern Med 2005;19:924927.
  • 19
    Allen MJ, Allen LC, Hoffmann WE, et al. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000;69:123127.
  • 20
    Ladlow JF, Hoffmann WE, Breur GJ, et al. Biological variability in serum and urinary indices of bone formation and resorption in dogs. Calcif Tissue Int 2002;70:186193.
  • 21
    Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:12281236.
  • 22
    Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43:154162.
  • 23
    Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281289.
  • 24
    Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharmacother 2005;39:11941197.
  • 25
    Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:16761679; discussion 1676–1679.
  • 26
    McDermott RS, Kloth DD, Wang H, et al. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 2006;4:524529.
  • 27
    Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003;9:23942399.
  • 28
    Smith MR. Zoledronic acid to prevent skeletal complications in cancer: Corroborating the evidence. Cancer Treat Rev 2005;31 (Suppl 3):1925.
  • 29
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377387.
  • 30
    Goblirsch MJ, Zwolak P, Clohisy DR. Advances in understanding bone cancer pain. J Cell Biochem 2005;96:682688.
  • 31
    Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:40384047.
  • 32
    Hogler W, Yap F, Little D, et al. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr 2004;145:701704.
  • 33
    Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 2005;35:2833.
  • 34
    Sorscher SM. Electrolyte abnormalities with zoledronic acid therapy. Cancer J 2002;8:348; author reply 348–349.